SOUTH SAN FRANCISCO, Calif., Feb. 14, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer. Under the terms of the agreement, OXiGENE will provide ZYBRESTAT to NCI for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance anti-tumor effects and further delay tumor progression when compared to bevacizumab alone. OXiGENE anticipates that investigators will initiate enrollment in this Phase 2 study in the first quarter of 2011. The primary endpoint of the study will be progression-free survival, with results expected to become available in early 2013.
Peter J. Langecker, M.D., Ph.D., OXiGENE Chief Executive Officer, commented: "Based on the encouraging data from both an earlier Phase 2 trial of ZYBRESTAT and chemotherapy in platinum-resistant ovarian cancer, and from our FALCON study of ZYBRESTAT plus bevacizumab in non-small cell lung cancer, we have been eager to continue exploration of combination therapy in patients with relapsed ovarian cancer, which is a highly difficult-to-treat disease. The finalization of this agreement is a critical milestone for OXiGENE, and exemplifies our strategy to leverage our assets through collaborations and continue to demonstrate the therapeutic potential of our vascular disrupting agents in major tumor types. We look forward to working with the GOG and NCI/CTEP to bring this new combination to patients."
Investigators from the GOG approached OXiGENE after seeing positive data from a Phase 2 study of ZYBRESTAT and chemotherapy in patients with platinum-resistant ovarian cancer. The study announced today is designed to investigate an alternative approach to treating relapsed ovarian cancer by exclusively targeting tumor vasculature without the use of chemotherapy.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV